| Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents. | |
| | |
MedLine Citation:
|
PMID: 11822749 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The efficacies and toxicities of anticancer agents vary greatly among patients. This is attributable to the activities of drug-metabolizing enzymes and membrane transporters, primarily determined by polymorphisms of the functions of genes encoding these proteins. DESIGN: We reviewed the available literature on drug-metabolizing enzymes and membrane transporters, especially their physiological functions, genetic and functional polymorphisms, and involvement in metabolism, pharmacokinetics and toxicity of anticancer agents. RESULTS: Nine enzymes metabolizing anticancer agents have been shown to have genetic polymorphisms: dihydropyrimidine dehydrogenase, cytochrome P450, NAD(P)H:quinone oxidoreductase 1, N-acetyltransferase 2, thiopurine methyltransferase, glutathione S-transferase, and uridine diphosphate glucuronosyltransferase. Decreased activities of these proteins can cause not only inherited metabolic disorders, but also extraordinarily severe toxicity in cancer patients given chemothearpy. Transporter proteins mediate cellular uptake and secretion of organic anions and cations. These proteins have recently been shown to play critical roles in the clearance of anticancer agents, although relations between patients' genetics backgrounds and the clinical significance of drug actions are poorly understood. CONCLUSIONS: Further studies should be focused on dosing and selection of anticancer agents, based on the type and extent of metabolic variation among individuals, in order to avoid adverse reactions and therapeutic failure. |
| | |
Authors:
|
I Sekine; N Saijo |
Related Documents
:
|
10219099 - Recent advances in the discovery and development of quinolones and analogs as antitumor... 3277209 - Metabolism of steroid-modifying anticancer agents. 17556909 - Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this ... 12964789 - Anticancer drug resistance of hela cells transfected with rat glutathione s-transferase... 19699249 - Development of hpma copolymer-anticancer conjugates: clinical experience and lessons le... 21673949 - Prokinetic drug utility in the treatment of gastroesophageal reflux esophagitis: a syst... 20415679 - Interferon-gamma (inf-gamma) release test can detect cutaneous adverse effects to statins. 20864169 - A strategy for precision engineering of nanoparticles of biodegradable copolymers for q... 16380209 - Trifluoperazine, an orally available clinically used drug, disrupts opioid antinocicept... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO Volume: 12 ISSN: 0923-7534 ISO Abbreviation: Ann. Oncol. Publication Date: 2001 Nov |
Date Detail:
|
Created Date: 2002-02-01 Completed Date: 2002-07-16 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9007735 Medline TA: Ann Oncol Country: England |
Other Details:
|
Languages: eng Pagination: 1515-25 Citation Subset: IM |
Affiliation:
|
Internal Medicine & Thoracic Oncology Division, National Cancer Center Hospital, Tokyo, Japan. isekine@gan2.ncc.go.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
metabolism* Carrier Proteins / genetics* Humans Metabolic Detoxication, Drug / genetics Oxidoreductases / genetics* Polymorphism, Genetic |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Carrier Proteins; EC 1.-/Oxidoreductases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of exogenous nitric oxide in experimental trichinellosis.
Next Document: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-...